MAP2K7 and cancer: The RAS/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase, i.e., MEK-ERK pathway, has been implicated in many cancers when aberrantly activated and is therefore a target for the development of antagonist drugs, such as the MEK inhibitor trametinib.2